Loading...

Publications

Loading...
  1. Arumugam GP, et al.: Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab 24:243-7, 2006.

  2. Cvitkovic F, et al.: Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 12:47-53, 2006.
     
  3. Van Poznak C: Hypercalcemia of malignancy remains a clinically relevant problem. Cancer J 12:21-3, 2006.
     
  4. Gucalp R: Hypercalcemia and gallium nitrate. J Support Oncol 2:518-20, 2004.
     
  5. Harvey HA, Almokadem SM: Hypercalcemia and gallium nitrate. J Support Oncol 2:516-7, 2004.
     
  6. Huang Z, Higgins B, Foss F: Activity of gallium nitrate in refractory peripheral T-cell lymphoma. Clin Lymphoma 6:43-5, 2005.
     
  7. Chitambar CR: Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. Oncology 18 (Suppl 10):39-44, 2004.

  8. Chitambar CR: Gallium compounds as antineoplastic agents. Curr Opin Oncol 16:547-52, 2004.

  9. Chitambar CR: Gallium nitrate for the treatment of non-Hodgkin's lymphoma. Expert Opin Investig Drugs 13:531-41, 2004.
     
  10. Einhorn L: Gallium nitrate in the treatment of bladder cancer. Semin Oncol. 30 (Suppl 5):34-41, 2003.

  11. Straus DJ: Gallium nitrate in the treatment of lymphoma. Semin Oncol 30 (Suppl 5):25-33, 2003.

  12. Leyland-Jones B: Treatment of cancer-related hypercalcemia: the role of gallium nitrate. Semin Oncol 30 (Suppl 5):13-9, 2003.

  13. Bockman R: The effects of gallium nitrate on bone resorption. Semin Oncol 30 (Suppl 5):5-12, 2003.

  14. Niesvizky R, et al.: Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrate. Leuk Lymphoma 43:603-5, 2002.
Loading...
Loading...
Loading...
Loading...
Mechanism of Action

Gallium reduces bone loss by inhibiting calcium resorption from bone. Preclinical evidence suggests that the mechanism of gallium action is multifactorial and different from other current therapies used to treat bone loss. 

 

Read More

Loading...
Preclinical Data

Drug disposition studies show that the active ingredient has a long plasma elimination half-life (101 hours in rat, 338 hours in dog).

Read More

Loading...
Loading...